Treatment of cancer using a CLL-1 chimeric antigen receptor

US10568947B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US

Inventors

• Jennifer Brogdon · Cambridge, US
• Hilmar Erhard Ebersbach · Basel, CH
• Saar Gill · Philadelphia, US
• David Glass · Cambridge, US
• Julia Jascur · Basel, CH
• Saad Kenderian · Philadelphia, US
• Joan Mannick · Cambridge, US
• Michael C. Milone · Cherry Hill, US
• Leon Murphy · Cambridge, US
• Celeste Richardson · Cambridge, US
• Reshma Singh · Cambridge, US
• Lai Wei · Kowloon, CN
• Qilong Wu · Shanghai, CN
• Qiumei Yang · Shanghai, CN
• Jiquan Zhang · Shanghai, CN

Key dates

• Filing date: Jul 21, 2015
• Grant date: Feb 25, 2020
• Expiry date: Oct 26, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/03
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.